Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5804830 | 0.81 | HSD17B10 (0.36) | HSD17B10SMN1; SMN2MAPTLMNA | |
| SCHEMBL313536 | 0.80 | MAPT (0.37) | HSD17B10SMN1; SMN2MAPTGAATP53 | |
| SCHEMBL4452232 | 0.80 | CDK1 (0.32) | HSD17B10LMNAHTT | |
| SCHEMBL9844627 | 0.80 | CDK1 (0.31) | — | |
| SCHEMBL10599233 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTLMNAGAAKDM4E | |
| SCHEMBL3732341 | 0.74 | HSD17B10 (0.31) | HSD17B10 | |
| SCHEMBL668620 | 0.74 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL10862753 | 0.73 | MAPT (0.38) | HSD17B10SMN1; SMN2MAPTLMNAGAA | |
| SCHEMBL6719673 | 0.73 | MAPT (0.38) | SMN1; SMN2MAPTLMNAGAAKDM4E | |
| SCHEMBL1088645 | 0.72 | HSD17B10 (0.30) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249959-B1 | PRODUCT | GIVAUDAN SA (CH) | 2016-04-13 | — | — | EP | disclosed |
| US-8357651-B2 | Aminoplast microcapsules containing fragrance | GIVAUDAN SA (CH) | 2013-01-22 | — | — | US | disclosed |
| US-20100323938-A1 | Product | GIVAUDAN SA (CH) | 2010-12-23 | — | — | US | disclosed |
| EP-2249959-A1 | PRODUCT | Givaudan SA (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009100553-A1 | PRODUCT | GIVAUDAN SA (CH) | 2009-08-20 | — | — | WO | disclosed |
| EP-1065227-B1 | Color improvement of dimethoxyethanal-melamine resins | CLARIANT FRANCE SA (FR) | 2004-09-01 | — | — | EP | disclosed |
| EP-1065227-A3 | Color improvement of dimethoxyethanal-melamine resins | Clariant (France) S.A. (FR) | 2002-07-31 | — | — | EP | disclosed |
| EP-1065227-A2 | Color improvement of dimethoxyethanal-melamine resins | Clariant (France) S.A. (FR) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323938-A1 | Product | SRM, PNMT, PFAS | HSD17B10 3552/4885SMN1; SMN2 1970/4885MAPT 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.